Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting

References

• Taylor PC, Balsa Criado A, Mongey AB, Avouac J, Marotte H, Mueller RB. How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient?-MTX in the treat-to-target strategy. J Clin Med. 2019;8(4). doi:10.3390/jcm8040515
   Web of Science ®Google Scholar
• Kruger K, Wollenhaupt J, Albrecht K, et al. [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol. 2012;71(7):592–603. German. doi:10.1007/s00393-012-1038-0
   Web of Science ®Google Scholar
• O’Dell JR, Curtis JR, Mikuls TR, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013;65(8):1985–1994. doi:10.1002/art.38012
   Web of Science ®Google Scholar
• Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013;124:16–25.
   PubMedGoogle Scholar
• Daien C, Hua C, Gaujoux-Viala C, et al. Update of french society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine. 2018.
   Google Scholar
• Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >/=15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73(8):1549–1551. doi:10.1136/annrheumdis-2014-205228
   PubMed Web of Science ®Google Scholar
• Osman A, Mulherin D. Is parenteral methotrexate worth trying? Ann Rheum Dis. 2001;60(4):432. doi:10.1136/ard.60.4.432
   Web of Science ®Google Scholar
• Bingham SJ, Buch MH, Lindsay S, Pollard A, White J, Emery P. Parenteral methotrexate should be given before biological therapy. Rheumatology. 2003;42(8):1009–1010. doi:10.1093/rheumatology/keg246
   Web of Science ®Google Scholar
• Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, Phase IV trial. Arthritis Rheum. 2008;58(1):73–81. doi:10.1002/art.23144
   PubMed Web of Science ®Google Scholar
• Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014;32(4):563–571.
   PubMed Web of Science ®Google Scholar
• Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B. Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia/Rheumatology. 2009;47(4):207–211.
   Google Scholar
• Chakravarty K, McDonald H, Pullar T, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology. 2008;47(6):924–925. doi:10.1093/rheumatology/kel216a
   PubMed Web of Science ®Google Scholar
• Contreras-Yanez I, Ponce De Leon S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci. 2010;340(4):282–290. doi:10.1097/MAJ.0b013e3181e8bcb0
   PubMed Web of Science ®Google Scholar
• Scheiman-Elazary A, Duan L, Shourt C, et al. The rate of adherence to antiarthritis medications and associated factors among patients with rheumatoid arthritis: a systematic literature review and metaanalysis. J Rheumatol. 2016;43(3):512–523. doi:10.3899/jrheum.141371
   Web of Science ®Google Scholar
• Mazaud C, Fardet L. Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials. Br J Dermatol. 2017;177(4):978–986. doi:10.1111/bjd.15377
   Web of Science ®Google Scholar
• Gossec L, Molto A, Romand X, et al. Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: a process based on literature reviews and expert consensus. Joint Bone Spine. 2019;86(1):13–19. doi:10.1016/j.jbspin.2018.08.006
   Web of Science ®Google Scholar
• Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73(4):388–395. doi:10.1016/j.jbspin.2006.01.007
   PubMed Web of Science ®Google Scholar
• Bello AE, Perkins EL, Jay R, Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol. 2017;9:67–79. doi:10.2147/OARRR.S131668
   PubMed Web of Science ®Google Scholar
• Berlowitz DR, Pajewski NM, Kazis LE. Intensive blood-pressure treatment and patient-reported outcomes. N Engl J Med. 2017;377(21):2097. doi:10.1056/NEJMoa1611179
   Web of Science ®Google Scholar
• Bress AP, Bellows BK, King JB, et al. Cost-effectiveness of intensive versus standard blood-pressure control. New Engl J Med. 2017;377(8):745–755. doi:10.1056/NEJMsa1616035
   PubMed Web of Science ®Google Scholar
• Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–354. doi:10.1111/j.1751-7176.2008.07572.x
   PubMed Web of Science ®Google Scholar
• Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol. 2011;64(3):255–257; discussion 258–263. doi:10.1016/j.jclinepi.2010.09.002
   Web of Science ®Google Scholar
• van der Heijde DM, van ‘T Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916–920. doi:10.1136/ard.49.11.916
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137–145. doi:10.1002/art.1780230202
   PubMed Web of Science ®Google Scholar
• Korb‐Savoldelli V, Gillaizeau F, Pouchot J, et al. Validation of a French version of the 8‐item Morisky medication adherence scale in hypertensive adults. J Clin Hypertens. 2012;14(7):429–434. doi:10.1111/j.1751-7176.2012.00634.x
   PubMed Web of Science ®Google Scholar
• Gadallah MA, Boulos DN, Dewedar S, Gebrel A, Morisky DE. Assessment of rheumatoid arthritis patients’ adherence to treatment. Am J Med Sci. 2015;349(2):151–156. doi:10.1097/MAJ.0000000000000376
   Web of Science ®Google Scholar
• Guillemin F, Coste J, Pouchot J, Ghezail M, Bregeon C, The SJ. AIMS2-SF: a short form of the arthritis impact measurement scales 2. french quality of life in rheumatology group. Arthritis Rheum. 1997;40(7):1267–1274. doi:10.1002/1529-0131(199707)40:7<1267::AID-ART11>3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Ward MM, Guthrie LC, Alba MI. Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis. 2015;74(9):1691–1696. doi:10.1136/annrheumdis-2013-205079
   Web of Science ®Google Scholar
• Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016;12(12):731–742.
   PubMed Web of Science ®Google Scholar
• Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, Furst DE. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci. 1989;78(2):165–171. doi:10.1002/jps.2600780219
   PubMed Web of Science ®Google Scholar
• Lebbe C, Beyeler C, Gerber NJ, Reichen J. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis. 1994;53(7):475–477. doi:10.1136/ard.53.7.475
   PubMed Web of Science ®Google Scholar
• Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645–648.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Barclay ML, O’Donnell JL, et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38(12):2540–2547. doi:10.3899/jrheum.110481
   PubMed Web of Science ®Google Scholar
• Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology. 2010;49(12):2337–2345. doi:10.1093/rheumatology/keq216
   PubMed Web of Science ®Google Scholar
• Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005;64(8):1180–1185. doi:10.1136/ard.2004.033399
   PubMed Web of Science ®Google Scholar
• De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol. 2016;35(5):1335–1339. doi:10.1007/s10067-016-3182-4
   Web of Science ®Google Scholar
• DiBenedetti DB, Zhou X, Reynolds M, Ogale S, Best JH. Assessing methotrexate adherence in rheumatoid arthritis: a cross-sectional survey. Rheumatol Ther. 2015;2(1):73–84. doi:10.1007/s40744-015-0011-1
   Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 american college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68(1):1–25. doi:10.1002/acr.22783
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977. doi:10.1136/annrheumdis-2016-210715
   PubMed Web of Science ®Google Scholar
• Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol. 1999;26(10):2114–2122.
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Nowell WB, Michel G, Wiedmeyer C. Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis. Ann Rheum Dis. 2018;77(5):678–683. doi:10.1136/annrheumdis-2017-212407
   PubMed Web of Science ®Google Scholar
• Goodacre LJ. Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication. Rheumatology. 2004;43(5):583–586. doi:10.1093/rheumatology/keh116
   Web of Science ®Google Scholar
• Gossec L, Berenbaum F, Chauvin P, et al. Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis. Clin Rheumatol. 2018;37(10):2649–2657. doi:10.1007/s10067-018-4172-5
   Web of Science ®Google Scholar
• Pasma A, den Boer E, van ‘T Spijker A, et al. Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients. Rheumatology. 2016;55(10):1812–1819. doi:10.1093/rheumatology/kew247
   Web of Science ®Google Scholar
• McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67(3):267–277. doi:10.1016/j.jclinepi.2013.08.015
   PubMed Web of Science ®Google Scholar